Research Stack

The Wolverine Stack (TB-500 + BPC-157): Research Mechanism and COA

Updated · 8 cited sources · ResearchChem Research Team

Short answer: The Wolverine Stack is ResearchChem's tissue-repair research blend: TB-500 (a synthetic version of the LKKTETQ actin-binding region of thymosin β-4) paired with BPC-157 (a 15-residue fragment of body protection compound from human gastric juice). The two come from unrelated parent molecules and have been studied separately in preclinical tissue-repair, cell-migration, and angiogenesis models — never head-to-head in the published literature. "Wolverine" is a product-name reference; every data point on the page is preclinical, and the vial ships at 20 mg combined for $100 with a lot-specific Certificate of Analysis on request.

What is in the Wolverine Stack?

  • SKU: WOLV-20. Size: 10 mg TB-500 + 10 mg BPC-157 in one vial (20 mg combined, lyophilized).
  • Price: $100 at /shop/wolverine.
  • Compliance line on the 40×20 mm label: "RESEARCH USE ONLY · NOT FOR HUMAN USE".
  • Storage: unopened at −20 °C; reconstitute with bacteriostatic water for in-vitro use.
  • COA: the lot-specific Certificate of Analysis is sent on request — email [email protected] with the lot number.

BPC-157 is not sold stand-alone at ResearchChem. Outside the Wolverine Stack it ships only inside KLOW 80 (BPC-157 + TB-500 + GHK-Cu + KPV, 80 mg combined, $120).

What TB-500 and BPC-157 are

TB-500 is described in the analytical literature as a synthetic preparation of LKKTETQ — a 7-amino-acid peptide corresponding to the central actin-binding region of thymosin β-4. Thymosin β-4 itself is a 43-amino-acid protein and the main actin-sequestering molecule in nearly all mammalian cells; its active sites include an amino-terminal tetrapeptide (Ac-SDKP), a 15-residue N-terminal fragment, and the central LKKTETQ domain (residues 17-23) linked in the parent-protein review to angiogenesis, wound healing, and cell migration [2]. TB-500 is built around that central actin-binding sequence [5].

BPC-157 is a pentadecapeptide — a 15-amino-acid fragment of body protection compound, a protein first isolated from human gastric juice. Its clearest mechanistic data come from tendon fibroblast cultures where it was reported to increase tendon-outgrowth in culture, improve cell survival under hydrogen-peroxide stress, increase migration in a dose-dependent transwell assay, and raise phosphorylation of focal adhesion kinase (FAK) and paxillin — leading the authors to propose that its effects run through the FAK-paxillin pathway [1]. A deeper BPC-157 primer is at BPC-157 research peptide.

Why the two ship together as a research blend

The design behind the pair is that BPC-157 and TB-500 converge on tissue-repair and cell-migration pathways from different directions. BPC-157 is studied as an upstream signaling modulator in the FAK-paxillin pathway with F-actin reorganization downstream [1]. TB-500 is built around the actin-binding sequence of a structural cytoskeletal protein [2][5]. In preclinical tissue-repair models the full-length thymosin β-4 protein — the parent of TB-500 — produced a 42% increase in re-epithelialization at day 4 and up to 61% at day 7 in rat full-thickness wounds vs controls, with more collagen deposition, more wound contraction, and more angiogenesis [3]; a synthetic 7-amino-acid peptide taken from the actin-binding domain produced similar benefits in db/db diabetic and aged mice [4].

A 2025 systematic review of 36 BPC-157 studies (35 preclinical, 1 clinical) described BPC-157 as supporting growth-factor signaling and angiogenesis and reducing inflammatory markers in muscle, tendon, ligament, and bone injury models [6]. The two peptides have not been compared head-to-head in the published literature; any synergy claim between them is not supported by a cited abstract — a point explicitly made in BPC-157 vs TB-500.

What the Wolverine Stack COA covers

The vial contains two different peptides, and the lot documentation should reflect that. A useful dual-component COA names each peptide, the lot number on the vial, and separate identity and purity results for each compound.

Fields a Wolverine Stack COA should carry
FieldWhat it tells youWhat to check
Lot numberWhich production run the vial belongs toMatches the lot printed on the vial
Compound 1 — BPC-157Which molecule was testedGEPPPGKPADDAGLV; monoisotopic ~1,419.5 Da
Compound 2 — TB-500Which molecule was testedAc-LKKTETQ sequence; theoretical mass ~889 Da (Ac-LKKTETQ)
Identity (MS)Measured molecular mass vs theoreticalObserved mass close to theoretical for each peptide
Purity (HPLC)Share of UV-absorbing material that is the main peakA percentage for each peptide plus the chromatogram
Methods and limitsHow each result was produced and the pass criterionAcceptance criteria next to every result
Lab, date, sign-offWho tested it and whenLab name, analysis date, analyst or QA signature

See how to read a peptide COA for a field-by-field walkthrough, and HPLC peptide purity explained for what the purity number does and does not report.

Regulatory status

Neither BPC-157 nor TB-500 is an approved drug anywhere. A 2026 review of approved and unapproved peptides marketed to patients lists both compounds alongside thymosin β-4 and notes that many show promising tissue-repair effects in animal studies but limited human safety data, and that patients could be seriously harmed [7]. The U.S. FDA placed BPC-157 arginate salt on its Category 2 list for 503A compounding — bulk substances raising significant safety risks under current review [8]. The Wolverine Stack vial is supplied strictly for in-vitro and animal research use.

Frequently asked questions

What is in the Wolverine Stack?

One vial containing 10 mg TB-500 and 10 mg BPC-157 (20 mg combined). TB-500 is a synthetic preparation of the central actin-binding region of thymosin β-4; BPC-157 is a 15-amino-acid fragment of body protection compound from human gastric juice.

Are BPC-157 and TB-500 the same thing?

No. They come from unrelated parent molecules and have not been compared head-to-head in the published literature. For a mechanism-focused comparison, see /research/bpc-157-vs-tb-500.

What does the Wolverine Stack COA show?

A dual COA names both peptides, the lot number on the vial, and separate identity (MS) and purity (HPLC) results for each compound. ResearchChem sends the lot-specific COA on request — email support with the lot number.

Are either of these compounds approved drugs?

No. Neither BPC-157 nor TB-500 is approved anywhere. Both are supplied for in-vitro and animal research use only.

Does ResearchChem sell BPC-157 or TB-500 alone?

No. Neither is sold stand-alone. BPC-157 ships inside the Wolverine Stack (with TB-500, 20 mg) and KLOW 80 (with TB-500 + GHK-Cu + KPV, 80 mg). TB-500 ships inside the same two stacks.

Cited studies

  1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.. J Appl Physiol (1985). 110(3):774-80 (2011). PubMed 21030672 DOI
  2. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences.. FASEB J. 24(7):2144-51 (2010). PubMed 20179146 DOI
  3. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing.. J Invest Dermatol. 113(3):364-8 (1999). PubMed 10469335 DOI
  4. Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice.. Wound Repair Regen. 11(1):19-24 (2003). PubMed 12581423 DOI
  5. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry.. J Chromatogr A. 1265:57-69 (2012). PubMed 23084823 DOI
  6. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.. HSS J. 21(4):485-495 (2025). PubMed 40756949 DOI
  7. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports Med. 56(8):1921-1935 (2026). PubMed 41966639 DOI
  8. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Category 2 (BPC-157 arginate).. FDA.gov (2023). Source

Related compounds

Keep reading

Research use only. ResearchChem products are laboratory reagents for in-vitro research. They are not for human or veterinary consumption and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published research for educational purposes and is not medical advice.